Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Anita Katharina Wagner, D.P.H., Dr.Pharm.

Co-Author

This page shows the publications co-authored by Anita Wagner and Christine Lu.
Connection Strength

3.142
  1. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015. Value Health. 2018 06; 21(6):692-697.
    View in: PubMed
    Score: 0.734
  2. Patient access schemes in Asia-pacific markets: current experience and future potential. J Pharm Policy Pract. 2015; 8(1):6.
    View in: PubMed
    Score: 0.608
  3. Uptake of new antidiabetic medications in three emerging markets: a comparison between Brazil, China and Thailand. J Pharm Policy Pract. 2015; 8(1):7.
    View in: PubMed
    Score: 0.608
  4. The Complex Cancer Care Coverage Environment - What is the Role of Legislation? A Case Study from Massachusetts. J Law Med Ethics. 2020 09; 48(3):538-551.
    View in: PubMed
    Score: 0.223
  5. Integrating public preferences into national reimbursement decisions: a descriptive comparison of approaches in Belgium and New Zealand. BMC Health Serv Res. 2020 Apr 25; 20(1):351.
    View in: PubMed
    Score: 0.218
  6. Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer. Breast Cancer Res Treat. 2018 Aug; 171(1):235-242.
    View in: PubMed
    Score: 0.190
  7. How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid? Clin Ther. 2015 Jul 01; 37(7):1420-1432.e1.
    View in: PubMed
    Score: 0.154
  8. Policies and programs to facilitate access to targeted cancer therapies in Thailand. PLoS One. 2015; 10(3):e0119945.
    View in: PubMed
    Score: 0.153
  9. Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans. Breast Cancer Res Treat. 2018 Sep; 171(2):449-459.
    View in: PubMed
    Score: 0.048
  10. Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment. J Clin Oncol. 2018 04 10; 36(11):1121-1127.
    View in: PubMed
    Score: 0.047
  11. Erratum to: Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. Breast Cancer Res Treat. 2016 11; 160(2):385.
    View in: PubMed
    Score: 0.043
  12. Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. Breast Cancer Res Treat. 2016 07; 158(2):333-40.
    View in: PubMed
    Score: 0.042
  13. Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis. BMJ Open. 2016 Mar 17; 6(3):e008671.
    View in: PubMed
    Score: 0.041
  14. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study. Health Policy. 2014 Jun; 116(2-3):196-205.
    View in: PubMed
    Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.